Both in Biotechnology
Maze Therapeutics vs Inhibrx Biosciences
Over the past year MAZE returned +7.2% and INBX returned +224.5%; their daily moves had a correlation of 0.14.
MAZE +7.2% INBX +224.5%Growth of $1, one year, split-adjusted
| Metric | MAZE | INBX |
|---|---|---|
| Price | $27.02 | $104.83 |
| Market cap | $1.50B | $1.54B |
| Today | +0.63% | +3.07% |
| 1 month | −1.5% | −15.1% |
| 6 months | −6.9% | +75.1% |
| Year to date | −34.8% | +32.7% |
| 1 year | +0.1% | +220.8% |
| Revenue growth (YoY) | — | −100.0% |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 75.0× | — |
| Net cash | $372.1M | -$42.9M |
| Dividend yield | — | — |
| Volatility (60d) | 66.4% | 67.6% |
| Short % of float | 14.2% | 36.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).